In vivo assessment of safety, biodistribution, and radiation dosimetry of the [F]Me4FDG PET-radiotracer in adults.

Background: Approaches targeting the sodium-glucose cotransporter (SGLT) could represent a promising future therapeutic strategy for numerous oncological and metabolic diseases. In this study, we evaluated the safety, biodistribution and radiation dosimetry of the glucose analogue positron emission tomography (PET) agent [F] labeled alpha-methyl-4-deoxy-4-[F]fluoro-D-glucopyranoside ([F]Me4FDG) with high sodium-glucose cotransporter and low glucose transporter (GLUT) affinity. For this purpose, five healthy volunteers (1 man, 4 women) underwent multiple whole-body PET/computed tomography (CT) examinations starting with injection and up to 4 h after injection of averaged (2.

FAPi PET/CT for assessment and visualisation of active myositis-related interstitial lung disease: a prospective observational pilot study.

Background: Interstitial lung disease (ILD) is a common manifestation of idiopathic inflammatory myopathies (IIM) and a substantial contributor to hospitalisation, increased morbidity, and mortality. In-vivo evidence of ongoing tissue remodelling in IIM-ILD is scarce. We aimed to evaluate fibroblast activation in lungs of IIM-patients and control individuals using ⁶⁸Ga-labelled inhibitor of Fibroblast-Activation-Protein (FAPi) based positronic emission tomography and computed tomography imaging (PET/CT).

Direct Patlak Reconstruction of [Ga]Ga-PSMA PET for the Evaluation of Primary Prostate Cancer Prior Total Prostatectomy: Results of a Pilot Study.

To investigate the use of kinetic parameters derived from direct Patlak reconstructions of [Ga]Ga-PSMA-11 positron emission tomography/computed tomography (PET/CT) to predict the histological grade of malignancy of the primary tumor of patients with prostate cancer (PCa). Thirteen patients (mean age 66 ± 10 years) with a primary, therapy-naïve PCa (median PSA 9.3 [range: 6.

Comparison of cardiac image-derived input functions for quantitative whole body [F]FDG imaging with arterial blood sampling.

Dynamic positron emission tomography (PET) and the application of kinetic models can provide important quantitative information based on its temporal information. This however requires arterial blood sampling, which can be challenging to acquire. Nowadays, state-of-the-art PET/CT systems offer fully automated, whole-body (WB) kinetic modelling protocols using image-derived input functions (IDIF) to replace arterial blood sampling.

Whole-body metabolic connectivity framework with functional PET.

The nervous and circulatory system interconnects the various organs of the human body, building hierarchically organized subsystems, enabling fine-tuned, metabolically expensive brain-body and inter-organ crosstalk to appropriately adapt to internal and external demands. A deviation or failure in the function of a single organ or subsystem could trigger unforeseen biases or dysfunctions of the entire network, leading to maladaptive physiological or psychological responses. Therefore, quantifying these networks in healthy individuals and patients may help further our understanding of complex disorders involving body-brain crosstalk.

Value of Ga-labeled bombesin antagonist (RM2) in the detection of primary prostate cancer comparing with [F]fluoromethylcholine PET-CT and multiparametric MRI-a phase I/II study.

Objectives: The bombesin derivative RM2 is a GRPr antagonist with strong binding affinity to prostate cancer (PCa). In this study, the impact of [Ga]Ga-RM2 positron emission tomography-computed tomography (PET-CT) for the detection of primary PCa was compared with that of [F]FCH PET-CT and multiparametric magnetic resonance imaging (mpMRI).

Methods: This phase I/II study was conducted in 30 biopsy-positive PCa subjects.

Response and Toxicity to the Second Course of 3 Cycles of Lu-PSMA Therapy Every 4 Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer.

Background: We investigated the response rate and degree of toxicity of a second course of three cycles of [Lu]Lu-PSMA radioligand therapy (PSMA-RLT) every 4 weeks in mCRPC patients.

Methods: Forty-three men (71.5 ± 6.

Additional Value of 2-[F]FDG PET/CT Comparing to MRI in Treatment Approach of Anal Cancer Patients.

Accurate staging and treatment planning are imperative for precise management in Anal Cancer (ACa) patients. We aimed to evaluate the additive and prognostic value of pre-treatment 2-[F]fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography (2-[F]FDG PET/CT) in the staging and management of ACa compared to magnetic resonance imaging (MRI). This retrospective study was conducted on 54 patients.

Diagnostic Performance of [F]Fluorocholine and [Ga]Ga-PSMA PET/CT in Prostate Cancer: A Comparative Study.

The current study endeavored to closely compare the detection rate of 68-Gallium labelled prostate-specific membrane antigen ([Ga]Ga-PSMA) versus [F]Fluorocholine in men with prostate cancer (PC), to investigate the benefits and pitfalls of each modality in the setting of various patient characteristics. We retrospectively analyzed 29 biopsy-proven PC patients in two categories, staging and restaging, who underwent both scans within a maximum of 30 days of each other. Variables including patient demographics, prostate specific antigen (PSA) level, Gleason score, clinical course, and following treatments were recorded.

Impact of contemporary therapy- concepts on surgical morbidity in breast cancer patients: A retrospective single center analysis of 829 patients.

Introduction: Morbidity after breast cancer surgery remains low with revision surgery below 5%. This retrospective monocentric study investigates whether new methods like neoadjuvant chemotherapy (nCT), oncoplastic surgery (OPS) or intraoperative radiotherapy (IORT) affect overall morbidity. In addition, we sought to determine a possible effect of morbidity on oncologic outcome.

Multiphasic Ga-PSMA PET/CT in the Detection of Early Recurrence in Prostate Cancer Patients with a PSA Level of Less Than 1 ng/mL: A Prospective Study of 135 Patients.

The main objective of this prospective study was to determine the impact of multiphasic acquisition of Ga-PSMA PET/CT in the detection of recurrent prostate cancer in the early stage of biochemical recurrence with a prostate-specific antigen (PSA) level of less than 1 ng/mL. Also, Ga-PSMA PET/CT positivity was correlated with clinical parameters for the assessment of predictive markers. A prospective monocentric study was conducted on 135 prostate cancer patients with biochemical recurrence and a PSA level of less than 1 ng/mL.

Molecular imaging of bone metastases using tumor-targeted tracers.

Bone metastasis is a disastrous manifestation of most malignancies, especially in breast, prostate and lung cancers. Since asymptomatic bone metastases are not uncommon, early detection, precise assessment, and localization of them are very important. Various imaging modalities have been employed in the setting of diagnosis of bone metastasis, from plain radiography and bone scintigraphy to SPECT, SPECT/CT, PET/CT, MRI.

[Imaging of parathyroid adenomas with F‑18 choline PET-CT].

Background: Ultrasound and sestamibi scintigraphy are the recommended standard procedures for initial diagnosis in primary hyperparathyroidism (pHPT). Recently, F‑18 choline positron emission tomography computed tomography (choline PET/CT) has been shown promising results for the diagnostic work up of primary hyperparathyroidism (pHPT) suggesting superiority over conventional scintigraphy using Tc99m sestamibi based protocols using planar dual-phase imaging, SPECT or SPECT/CT.

Methods: This review presents the results of F‑18 choline PET/CT on the basis of a literature search using the keywords "primary hyperparathyroidism and choline", "primary hyperparathyroidism and PET", "parathyroid adenoma and choline" und "parathyroid adenoma and PET".

F-Fluorocholine PET/CT in the assessment of primary hyperparathyroidism compared with Tc-MIBI or Tc-tetrofosmin SPECT/CT: a prospective dual-centre study in 100 patients.

Purpose: In this prospective study we compared the accuracy of F-fluorocholine PET/CT with that of Tc-MIBI orTc-tetrofosmin SPECT/CT in the preoperative detection of parathyroid adenoma in patients with primary hyperparathyroidism. We also assessed the value of semiquantitative parameters in differentiating between parathyroid hyperplasia and adenoma.

Methods: Both F-fluorocholine PET/CT and Tc-MIBI/tetrofosmin SPECT/CT were performed in 100 consecutive patients with biochemical evidence of primary hyperparathyroidism.

Optimal time-point for Ga-PSMA-11 PET/CT imaging in assessment of prostate cancer: feasibility of sterile cold-kit tracer preparation?

Purpose: In this prospective study, we evaluated the optimal time-point for Ga-PSMA-11 PET/CT acquisition in the assessment of prostate cancer. We also examined, for the first time the feasibility of tracer production using a PSMA-11 sterile cold-kit in the clinical workflow of PET/CT centres.

Methods: Fifty prostate cancer patients (25 staging, 25 biochemical recurrence) were enrolled in this study.

Role of Pepsin and Oropharyngeal pH-Monitoring to Assess the Postoperative Outcome of Patients with Laryngopharyngeal Reflux: Results of a Pilot Trial.

Background: The aim of this study was to evaluate the value of salivary pepsin and oropharyngeal pH-monitoring to assess the surgical outcome of patients with laryngopharyngeal reflux (LPR).

Materials And Methods: Twenty consecutive patients with LPR despite proton pump inhibitor treatment received laparoscopic antireflux surgery. Twenty-four hour esophageal pH-monitoring (multichannel intraluminal impedance monitoring [MII]-pH) and esophageal manometry (high-resolution manometry) data were documented preoperatively and at 3-month follow-up.

Therapy assessment of bone metastatic disease in the era of radium.

Purpose: Defining an optimal imaging modality for assessment of therapy and the best time of evaluation are pivotal for ideal patient's management.

Methods: Ra (Xofigo®, formerly Alpharadin) has been approved by the FDA and European Medicines Agency for treatment of metastatic castration-resistant prostate cancer with painful osseous involvement.

Results: PET/CT imaging using various radiotracers such as F-FDG, F-FCH, Ga-PSMA and F-NaF have been investigated to mitigate the limitations of conventional imaging modalities.

68Ga-PSMA-HBED Uptake on Cervicothoracic (Stellate) Ganglia, a Common Pitfall on PET/CT.

Ga-PSMA-HBED PET/CT showed promising results in staging and restaging of prostate cancer. However, nonspecific uptake has been reported in the celiac ganglia. In this case series, we showed faint radiotracer uptake on upper thoracic region in the location of cervicothoracic (stellate) ganglia.

F-NaF-PET/CT and Tc-MDP Bone Scintigraphy in the Detection of Bone Metastases in Prostate Cancer.

Tc-MDP whole-body bone scintigraphy is a highly sensitive imaging method that has been used for decades to evaluate prostate cancer bone metastasis based on its availability and low cost; however, because of accumulation of this radiotracer in degenerative, traumatic, and inflammatory lesions, it suffers from noncomparable specificity. The modality is also used to monitor response to therapy and to predict patients' prognosis. As planar imaging may not give enough information for lesion detection or anatomical localization, it can be supplemented with SPECT to increase image contrast particularly in the evaluation of small and complex skeleton.

Evaluation of Prostate Cancer Bone Metastases with 18F-NaF and 18F-Fluorocholine PET/CT.

F-fluorocholine is a specific promising agent for imaging tumor cell proliferation, particularly in prostate cancer, using PET/CT. It is a beneficial tool in the early detection of marrow-based metastases because it excludes distant metastases and evaluates the response to hormone therapy. In addition, F-fluorocholine has the potential to differentiate between degenerative and malignant osseous abnormalities because degenerative changes are not choline-avid; however, the agent may accumulate in recent traumatic bony lesions.